Kaplan–Meier survival analysis based on TGase 2 expression revealed that disease-free survival (DFS) in the TGM2 over-expressing group was shorter than that in the normal expression group (89.8 months vs. 123.7 months, respectively; p = 0.0136), see Figure 1C. Overall, 47.2% of renal cancers overexpressed TGM2, which is very high. This evidence concerns the gene TGM2 and renal carcinoma.